Multinational drug company rebutted bridging clinical study.

Published: 1999-05-10 11:19:00

Updated: 1999-05-10 11:19:00

The multinational pharmaceutical corporations strongly resisted against the KFDA's bridging study program recently announced in public, which should be performed only for Korean ethnic patients living in domestic or overseas locations as an improvement of the current registration system for a new...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK